Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Jul-Aug;36(7):425-30.
doi: 10.1016/j.acuro.2011.09.008. Epub 2012 Mar 3.

[Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer]

[Article in Spanish]
S C H Park  1 , L J Whan, R J Sik
Affiliations
Comparative Study

[Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer]

[Article in Spanish]
S C H Park et al. Actas Urol Esp. 2012 Jul-Aug.

Abstract

Introduction: The aim of this study was to determine the efficacy and safety of docetaxel-based systemic chemotherapy in elderly patients with castration-resistant prostate cancer (CRPC).

Material and methods: We retrospectively reviewed the clinical records of 36 patients with CRPC who were treated with docetaxel-based systemic chemotherapy at a single institution between May 2005 and April 2010. After screening, 30 patients met the eligibility criteria, and were included. Patients were placed into 2 groups: group 1 consisted of 9 patients aged <70 years, and group 2 consisted of 21 patients aged ≥70 years. The treatment consisted of prednisolone (5mg) twice daily and docetaxel (75 mg/m(2)) once every 3 weeks.

Results: The median age was 72 years, and the median performance status was 0. The median baseline prostate specific antigen (PSA) was 33.8 ng/mL. The mean number of docetaxel chemotherapy cycles was 5.8. The PSA response rate was 48.2%, and the measurable disease response rate was 15.0%, and these rates did not differ between the two groups. The median time to PSA progression and median overall survival were 6 and 9 months, respectively. Five patients experienced grade 3 or higher neutropenia. The drug-related toxicity was not different between the two groups.

Conclusions: The response of elderly CRPC patients with good performance status to docetaxel-based systemic chemotherapy was similar to that of younger patients. Docetaxel-based systemic chemotherapy is generally tolerated in elderly patients with good performance status.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Publication types

LinkOut - more resources